Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05636176 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Study acronym: HERMES
StatusTerminated
PhasePhase 3
Started2023-05-08
View on ClinicalTrials.gov ↗
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.

Amendment history 5 changes detected by DataLookout

2026-09-11
critical
Trial terminated: No longer looking for participants.
2026-09-11
minor
Primary completion confirmed: September 2026 (last estimated July 2027)
2026-07-08
notable
Trial status changed: Recruiting → Active, Not Recruiting
2026-07-08
notable
Enrollment reduced: 5600 → 4899 participants
2026-07-08
minor
Trial sites reduced: 1117 → 1013 locations
Trial Details
NCT Number NCT05636176
Lead Sponsor Novo Nordisk A/S
Conditions Heart Failure
Enrollment 4,899 participants
Start Date 2023-05-08
Primary Completion 2026-09-03 (estimated)
Study Completion 2026-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-10